Trial Profile

A study to assess the anti-albuminuric effects and variability in response to dapagliflozin in subjects with type 2 diabetes

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapagliflozin (Primary)
Indications Type 2 diabetes mellitus
Focus Pharmacodynamics
Acronyms IMPROVE

Most Recent Events

01 Aug 2021 Results of post-hoc exploratory analysis of three randomized studies (DELIGHT (NCT02547935), IMPROVE (Netherlands Trial Register NTR4439) and DIAMOND (NCT03190694)) published in the Diabetes, Obesity and Metabolism.
01 Jan 2018 Status changed from recruiting to completed, according to results published in the Diabetes, Obesity and Metabolism.
07 Jun 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2014-000157-37)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com